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To the Editor: Aquatic birds form a natural reservoir 
of avian influenza viruses from which new human and 
animal influenza viruses originate. After initial detection 
in 2010 in China, a new highly pathogenic avian influenza 
(HPAI) virus of the H5N8 subtype reemerged in ducks 
in South Korea in 2014 (1,2). The hemagglutinin gene 
of this virus was distantly related to those of H5N1 sub-
types that have caused infections in humans since 1997 
(3). The World Health Organization/World Organisation 
for Animal Health/Food and Agriculture Organization of 
the United Nations H5N1 Evolution Working Group has 
assigned this new H5 to clade 2.3.4.4. Several poultry 
farms in the Netherlands, Germany, United Kingdom, and 
Italy were recently affected by infection with H5N8 virus 
closely related to the strains circulating in Asia (4), lead-
ing to implementation of preventive measures to restrict 
viral spread. Human infections with this new HPAI sub-
type have not been reported.
Modified vaccinia virus Ankara (MVA) is a promising 
viral vector platform for the development of influenza vac-
cines (5). We previously conducted a randomized double-
blind phase 1/2a trial in young healthy persons to evaluate 
an MVA-based H5 vaccine (registered in the Netherlands’ 
trial register under NTR3401). Preclinical testing was con-
ducted before this trial (6,7). Thirty-nine study participants 
received MVA-H5-serumfree Munich-Rotterdam (sfMR), 
which encoded hemagglutinin of influenza virus A/Viet-
nam/1194/2004 (H5N1), and 40 received vector control. 
Persons received 1 or 2 doses (with an interval of 4 weeks) 
of 107 or 108 PFU. Twenty-seven of the MVA-H5-sfMR– 
vaccinated persons received a booster vaccination 1 year 
later (again 107 or 108 PFU). The MVA-based vaccine was 
well tolerated and induced antibodies to both the homologous 
(A/Vietnam/1194/2004, clade 1) and a heterologous 
(A/Indonesia/5/2005, clade 2.1) H5N1 virus (8).
Although the newly emerged HPAI (H5N8) vi-
rus thus far has been detected only in birds, zoonotic 
transmission to humans exposed to large numbers of 
infected birds might occur (e.g., during culling opera-
tions). Therefore, shortly after the H5N8 outbreak in 
poultry in the Netherlands, we determined whether 
MVA-H5-sfMR–induced antibodies cross-react with the 
new H5N8 strain. Post-infection A/Vietnam/1194/2004 
(clade 1) ferret serum (infected with a low pathogenic 
reverse genetics virus produced with hemagglutinin and 
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Figure. Results of hemagglutination-inhibition (HI) testing of modified vaccinia virus Ankara influenza vaccine cross-reactivity. Each 
symbol represents a person in the clinical trial; symbol shapes indicate different vaccination regimens. A) Timeline for development  
of HI titers against influenza virus A(H5N8) (A/chicken/Netherlands/EMC-3/2014). B) Correlation between HI titers against H5N8 and  
A/Vietnam/1194/2004 (H5N1) viruses. Linear regression for samples after booster vaccination is shown (r = 0.82, p<0.0001).
neuraminidase gene segments of A/Vietnam/1194/2004 
and the remaining 6 gene segments of A/Puerto 
Rico/8/34) was tested by hemagglutination-inhibition 
(HI) for cross-reactivity with viruses belonging to clade 
0 (A/Hong Kong/156/1997), 2.1 (A/Indonesia/5/2005), 
2.2 (A/Turkey/turkey/1/2005), and 2.3 (A/Anhui/1/2005) 
and the emerging H5N8 strain A/chicken/Netherlands/
EMC-3/2014. A/Vietnam/1194/2004-specific serum (ho-
mologous titer 80) displayed low cross-reactivity with the 
clade 0, 2.2, and 2.3 viruses and completely failed to react 
with H5N8 strain A/chicken/Netherlands/EMC-3/2014. 
Inversely, A/chicken/Netherlands/EMC-3/2014-specific 
ferret serum (homologous titer 160) completely failed 
to cross-react with A/Vietnam/1194/2004. This finding 
demonstrates an antigenic distance between these viruses. 
Furthermore, the World Health Organization Collaborat-
ing Centers have only found limited cross-reactivity of a 
panel of H5 vaccine candidates with subtype H5N8 (9).
The clinical trial serum samples were pretreated with 
receptor-destroying enzyme and horse erythrocytes and 
tested by HI assay for their reactivity with A/chicken/
Netherlands/EMC-3/2014 according to standard proce-
dures (10). HI antibodies were induced after MVA-H5-
sfMR vaccination that displayed considerable reactivity 
with the antigenically distinct H5N8 strain A/chicken/
Netherlands/EMC-3/2014 (Figure, panel A). The titers 
of cross-reactive antibodies correlated with those to 
the homologous strain A/Vietnam/1194/2004 (r = 0.82, 
p<0.0001; Figure, panel B).
As shown previously (8), the magnitude of the an-
tibody response was dose-dependent. Also, the highest 
cross-reactive response to the H5N8 strain was observed 
after vaccination with 108 PFU (Figure, panel A) of MVA-
H5. None of the study participants had prevaccination HI 
antibody titers >1:40 against A/Vietnam/1194/2004 or A/
chicken/Netherlands/EMC-3/2014. Although most of the 
study participants had detectable HI antibody titers against 
the homologous virus 4 and 8 weeks after vaccination (8), 
antibodies against the H5N8 virus were barely detectable at 
these time points. HI antibody titers against the homologous 
virus increased in persons who received a booster vaccine 
at 52 weeks after primary vaccination. A large proportion 
(9 [82%] of 11 study participants; geometric mean titer 63) 
of participants who received a vaccine dose of 108 PFU 
(equally divided among groups that received 1 or 2 pre-
vious doses) also had detectable cross-clade titers against 
the H5N8 virus A/chicken/Netherlands/EMC-3/2014. Fur-
thermore, virus neutralizing antibodies against H5N8 virus 
were detected in 10 of 27 persons and correlated with anti-
body titers measured by HI assay.
We showed that an MVA-based H5 (A/Viet-
nam/1194/2004) vaccine can elicit cross-clade antibodies 
against the newly emerging HPAI (H5N8) virus that is 
genetically and antigenically distinct from the clade 1 
H5N1 virus A/Vietnam/1194/2004. The cross-reactive an-
tibody response observed after the 1-year booster vaccina-
tion suggests that the use of MVA-H5-sfMR is an effective 
emergency vaccination strategy in case tailor-made vac-
cines are not yet available in an outbreak situation. Thus, 
such a strategy might also be effective against the newly 
emerging influenza A(H5N8) viruses, in case these viruses 
would cause human infections.
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To the Editor: Carbapenemase-producing Enterobac-
teriaceae are being reported worldwide. Travel, medical 
tourism, and cross-border transfer of patients might play a 
role in the spread of these bacteria (1,2). Klebsiella pneu-
moniae co-producing New Delhi metallo-β-lactamase 5 
(NDM-5) and oxacillinase 181 (OXA-181) carbapenemas-
es was detected in South Korea in 2014.
On April 13, a 75-year-old man who had had a cere-
bral infarction was transferred from a tertiary care hospital 
in Abu Dhabi, United Arab Emirates (UAE), to Samsung 
Medical Center (Seoul, South Korea) for rehabilitation 
therapy. In Abu Dhabi, he had received broad-spectrum 
antimicrobial drugs for aspiration pneumonia. While at 
Samsung Medical Center, he experienced septic shock and 
acute respiratory failure due to pneumonia and was trans-
ferred to the medical intensive care unit (ICU). Carbapen-
em-resistant K. pneumoniae (strain CC1409-1) was isolat-
ed from a culture of bronchoalveolar lavage fluid. He was 
given meropenem and colistin for treatment of pneumonia, 
was discharged, and returned to the UAE.
Four months later, carbapenem-resistant K. pneumoni-
ae (strain CC1410-1) was identified in the tracheal aspirate 
of a 74-year-old woman admitted to the surgical ICU at 
Samsung Medical Center for traumatic intracranial hemor-
rhage. She had no underlying disease or previous history 
of hospitalization or travel abroad. She was given colistin 
and piperacillin/tazobactam. Following the identification 
of colistin resistance, colistin was switched to tigecycline. 
However, her clinical condition worsened (aggravated 
pneumonia), and she died of refractory respiratory failure.
In vitro antimicrobial drug susceptibility tests of 2 
isolates were performed by using broth microdilution. Re-
sults were interpreted following Clinical and Laboratory 
Standards Institute guidelines (3), except for those for 
colistin and tigecycline, for which European Committee 
on Antimicrobial Susceptibility Testing breakpoints were 
used (4). The first isolate was susceptible to colistin but 
none of the other antimicrobial agents tested (cefepime, 
ceftriaxone, ceftazidime, aztreonam, amikacin, cipro-
floxacin, trimethoprim/sulfamethoxazole, ertapenem, 
imipenem, and meropenem)whereas the second isolate 
was susceptible only to tigecycline. Modified Hodge tests 
for both isolates showed positive results. Production of 
metallo-β-lactamase was detected by an imipenem-EDTA 
double-disk synergy test.
The presence of carbapenemase genes was determined 
by PCR and DNA sequencing (2). The bla
NDM
 and bla
OXA-48
 
genes were detected in both isolates. The PCR product 
sequences were consistent with those of NDM-5 (Gen-
Bank accession no. JN104597.1) and OXA-181 (GenBank 
accession no. JN205800.1). Further analyses for other 
β-lactamases (TEM-type, SHV-type, and CTX-type) and 
16S rRNA methylase aminoglycoside resistance determi-
nants (armA, rmtA, rmtB, rmtC, rmtD, rmtF, and npmA) 
revealed that both isolates carried bla
TEM-1
, bla
SHV-11
, bla 
CTX-M-15
, and rmtB genes.
Clonal relatedness was investigated by using multilo-
cus sequence typing and pulsed-field gel electrophoresis 
(PFGE) (5,6). Multilocus sequence typing revealed that 
both isolates belonged to sequence type 147. PFGE showed 
that both isolates were the same strain (Figure).
The 2 patients were never hospitalized in the same ward 
and there was a substantial time lag between their hospital-
izations. However, given sequence type and PFGE patterns 
between 2 isolates, we suspected nosocomial cross-trans-
mission and performed infection control measures, includ-
ing strict contact precautions and enhanced environmental 
cleaning with daily monitoring in the surgical ICU. In addi-
tion, environmental cultures and active surveillance cultures 
(rectal swabs and respiratory samples) on all patients in the 
units where these isolates were identified were performed to 
find asymptomatic carriers or contaminated environments as 
potential sources of transmission. All samples tested were 
negative for carbapenemase-producing Enterobacteriaceae. 
No further cases were reported in the hospital.
NDM-5 was first identified in a multidrug-resistant 
Escherichia coli sequence type 648 isolate from a patient in 
the United Kingdom who had a recent history of hospital-
ization in India (7). NDM-5 differs from existing enzymes 
due to substitutions at positions 88 (Val→Leu) and 154 
(Met→Leu). OXA-181, a variant of OXA-48, was initially 
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